TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  05/23 10:30:00 pm EDT
3786.00 JPY   -0.63%
05/12Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Projects Decline Next Fiscal
MT
05/11Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%
MT
05/11GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : to begin trial against virus in summer with global partners

05/08/2020 | 06:48am EDT

Takeda Pharmaceutical Co. said Friday it is expected to begin this summer a study of a plasma-derived therapy for adult patients of the novel coronavirus with its global partners.

The international alliance involving 10 plasma companies, such as Biotest and CSL Behring, will work with the National Institute of Allergy and Infectious Diseases in the United States to test the therapy's safety and efficacy.

The study uses blood from patients who have recovered from the pneumonia-causing respiratory disease, according to Takeda.

"Hyperimmune globulin therapy has the potential to be one of the earliest treatment options for COVID-19," Bill Mezzanotte, executive vice president of CSL Behring, said in a statement.

The group, formed to accelerate the development and distribution of the treatment for COVID-19 patients, is calling for donations of convalescent plasma.

"We now have enough plasma to initiate clinical manufacturing, but more is needed to ensure both speed and scale," said Julie Kim, president of Takeda's Plasma-Derived Therapies Business Unit and co-leader of the alliance.

==Kyodo

© Kyodo News International, Inc., source Newswire

All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
05/12Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Project..
MT
05/11Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%
MT
05/11GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q4 2022 Earnings Call, May 11, 2022
CI
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, 2022 Earnings Call, May 11, 2022
CI
05/11Takeda Pharmaceutical Posts Higher Profit, Revenue in Fiscal 2021
MT
05/11Takeda Pharmaceutical Posted Fourth-Quarter Net Loss
DJ
05/11Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
BU
05/11Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the F..
CI
05/11Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 20..
CI
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 490 B 27 321 M 27 321 M
Net income 2022 239 B 1 870 M 1 870 M
Net Debt 2022 3 299 B 25 821 M 25 821 M
P/E ratio 2022 24,9x
Yield 2022 4,72%
Capitalization 5 881 B 46 035 M 46 035 M
EV / Sales 2022 2,63x
EV / Sales 2023 2,42x
Nbr of Employees 47 099
Free-Float 97,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 3 810,00 JPY
Average target price 4 402,67 JPY
Spread / Average Target 15,6%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED18.87%45 016
JOHNSON & JOHNSON4.89%465 705
PFIZER, INC.-10.45%294 404
ELI LILLY AND COMPANY9.55%269 013
ABBVIE INC.9.33%266 851
ROCHE HOLDING AG-15.67%266 707